An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
Nicholas James ShortJayastu SenapatiElias JabbourPublished in: Current hematologic malignancy reports (2023)
Later-generation, more potent BCR::ABL1 tyrosine kinase inhibitors (TKIs) such as ponatinib may result in superior outcomes in patients with advanced phase CML. For CML-BP, combination approaches directed against the blast immunophenotype appear superior to TKI monotherapy. The role of allogeneic stem cell transplantation is controversial in CML-AP but has consistently been shown to improve outcomes for patients with CML-BP. Advanced phase CML, particularly CML-BP, remains a poor risk subtype of CML. However, novel combination approaches using later-generation TKIs are being explored in clinical trials and may lead to improved outcomes.
Keyphrases
- chronic myeloid leukemia
- stem cell transplantation
- clinical trial
- high dose
- transcription factor
- bone marrow
- type diabetes
- low dose
- acute lymphoblastic leukemia
- metabolic syndrome
- combination therapy
- anti inflammatory
- study protocol
- advanced non small cell lung cancer
- hematopoietic stem cell
- double blind
- placebo controlled